Welcome to Advanced Memory Research Institute of New Jersey

FREE MEMORY EVALUATION

Our site offers free memory screenings to you or a loved one to help address concerns about memory loss. Our staff will conduct basic memory tests to establish a clinical picture.

Dr. Sharma will then sit with you to discuss the results of the test, answer questions about your concerns, and discuss possible participation in a clinical trial.


Call us Today to schedule an appointment!

732-341-9500

AstraZeneca AZ D5010C00009

A 24-month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer’s disease (The AMARANTH Study)

RAmP F-AV-45-A25

Registry of Amyloid Positive Patients for Alzheimer’s disease drug Research Trials (RAmP)

Biogen 221AD103

A Randomized, Double-Blind, Placebo-controlled Multi Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in subjects With Prodromal or Mild Alzheimer’s Disease.

Biogen 221AD301

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's disease.

BAC-02

A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate the Efficacy and Safety of BAC in Patient with Alzheimer’s disease or Vascular Dementia.

Eisai BAN2401-G000-201

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease.

Eisai E2006-G000-202

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer’s Disease Dementia.

Eisai E2609-G000-302

A Placebo-Controlled, Double–Blind, Parallel Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.

17X-MC-LLCF

Effect of LY3202626 on Alzheimer’s disease Progression as Measured by Cerebral 1451 Tau-PET in Mild Alzheimer’s disease Dementia.

DAYBREAK-ALZ 18D-MC-AZET

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s disease Dementia (The DAYBREAK Study).

18D-MC-AZFD

A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s disease Dementia (Extension of Study AZES, The AMARANTH Study).

Ideas

Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study. A coverage with Evidence Development Longitudinal Cohort Study.

Roche BN29552

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease.

Suven CTP2S1502HT6

A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 23-Week, Placebo-Controlled Study of 50mg and 100mg of SUVN-502 in subjects with moderate Alzheimer’s Disease Currently treated with Donepezil hydrochloride and Mementin hydrochloride.

Meet the Staff

Dr. Sanjiv Sharma is assisted by a skillful team that has over twenty years of clinical research experience and is always ready and willing to answer any questions or concerns that you may have.

Patient Testimonial

"I was bothered by my forgetfulness. Was I destined for Alzheimer’s Disease? I'm too active of a person, too involved in life to think that was my destiny.
I knew I had to do something about what was happening to my memory, before it got any worse.
That’s when I found Dr. Sanjiv Sharma at the Advanced Memory Research Institute of New Jersey.
I learned there were many treatments available for the kind of forgetfulness I was experiencing."

- A Thankful Patient

Follow us on Facebook